How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out.

@article{Kegeles2006HowSH,
  title={How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out.},
  author={Susan M. Kegeles and Mallory O Johnson and Ronald P. Strauss and Brady Ralston and Robert B Hays and David S. Metzger and Eleanor McLellan-Lemal and Kathleen M. MacQueen},
  journal={AIDS education and prevention : official publication of the International Society for AIDS Education},
  year={2006},
  volume={18 6},
  pages={560-72}
}
Developing an effective vaccine remains a critical long-term approach to HIV prevention. Every efficacy trial should be responsive to the concerns of participating communities because the successful development of an HIV preventive vaccine will require long-term involvement of people who have been marginalized and who distrust the government and biomedical research. Using qualitative interviews and purposive sampling, we elicited recommendations regarding how vaccine efficacy trials should be… CONTINUE READING